Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

March 16, 2018: By Joan McKenna

Bar-Ilan University in Israel announced March 8 that it is developing an eye drop filled with synthetic nanoparticles as a non-invasive method to correct refractive errors.

Researchers previously described their work at the 2017 meeting of the European Society of Cataract and Refractive Surgeons.

The eye drops, branded Nano-Drops, work in conjunction with a laser source to apply an optical pattern to the superficial layer of the corneal epithelium to change the refractive index, or the trajectory of light passing through the cornea, according to developers. Surgeons can adjust the shape of the pattern for correction of myopia, hyperopia, or presbyopia.

The university said the laser stamping takes a few milliseconds.

Bar-Ilan said a future use might consist of patients having their vision corrected in the comfort of their own home. The school envisions patients opening an application on their smartphone to measure their vision, connecting the laser source device for stamping the optical pattern at the desired correction, and applying the Nano-Drops to activate the pattern and provide the desired correction.

The university said the technology has shown through ex-vivo experiments that it can correct nearly 3 diopters of myopia and presbyopia in pig eyes.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility